NCT00382070 · OUTCOME

Disease-free Survival

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer · Source last updated 2024-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of patients free of disease
Interval / dispersion: Not reported
Time frame: 7 years.

What was measured

Percentage of patients free from DFS events. DFS events include local, regional, or distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer.

Groups in this outcome

Group 2 Letrozole

Patients receive oral letrozole once daily for up to 5 years. Letrozole: Letrozole 2.5 mg taken orally once daily for 5 years

Group 1 Placebo

Patients receive oral placebo once daily for up to 5 years. Placebo: Placebo tablet taken orally once daily for 5 years

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Group 2 Letrozole	1950
Group 1 Placebo	1953

Reported measurements

Source class 1

Values in percentage of patients free of disease · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Group 2 Letrozole	84.7	Not reported	Not reported	Not reported	Not reported
Group 1 Placebo	81.3	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
84.7
group Id
OG001
value
81.3

denoms

counts
group Id
OG000
value
1950
group Id
OG001
value
1953
units
Participants

description

Percentage of patients free from DFS events. DFS events include local, regional, or distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer.

groups

description
Patients receive oral letrozole once daily for up to 5 years. Letrozole: Letrozole 2.5 mg taken orally once daily for 5 years
id
OG000
title
Group 2 Letrozole
description
Patients receive oral placebo once daily for up to 5 years. Placebo: Placebo tablet taken orally once daily for 5 years
id
OG001
title
Group 1 Placebo

param Type

NUMBER

reporting Status

POSTED

time Frame

7 years.

title

Disease-free Survival

type

PRIMARY

unit Of Measure

percentage of patients free of disease

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice